Open Access Article
This Open Access Article is licensed under a
Creative Commons Attribution 3.0 Unported Licence

Heterocycle-derived β-S-enals as bifunctional linchpins for the catalytic synthesis of saturated heterocycles

Jingze Niu and Michael C. Willis *
Department of Chemistry, University of Oxford, Chemical Research Laboratory, Mansfield Road, Oxford, OX1 3TA, UK. E-mail: michael.willis@chem.ox.ac.uk

Received 4th February 2016 , Accepted 11th March 2016

First published on 23rd March 2016


Abstract

We demonstrate how heterocycle-derived β-S-enals can be employed as bifunctional substrates in a cascade of two rhodium-catalysed C–C bond forming reactions to deliver substituted heterocyclic products. A single rhodium-catalyst, generated in situ from a commercial salt and ligand combination, is used to promote both an initial alkene or alkyne hydroacylation reaction, and then a Suzuki-type cross-coupling, resulting in a three-component assembly of the targeted heterocycles. Substrates based on N-, O- and S-heterocycles are included, as are a range of alkenes, alkynes and boronic acid derivatives.


Due to the favourable physiochemical properties often associated with their incorporation into candidate structures, saturated, or partially saturated, heterocycles are becoming increasingly targeted in drug discovery programs.1 Their presence in biologically active molecules has significant precedent, and Scheme 1 shows several examples of N-, O- and S-heterocycles embedded in pharmaceuticals and natural products used in a variety of applications.2 The N-based congeners such as pyrrolidines, piperidines, and tropanes are the most commonly encountered structures.3
image file: c6qo00057f-s1.tif
Scheme 1 Saturated and partially saturated heterocycles in pharmaceuticals and natural products.

In order to access saturated and partially saturated heterocycles decorated with a variety of substituents, we conceived an approach based on a common class of bifunctional building blocks that could be elaborated using cascade catalytic reactions. The key building blocks that we settled on were heterocycle-derived β-S-enals (1, Scheme 2). Variants of 1 featuring N, O, and S-atoms are all accessible from the parent ketones using established methods.4 With the key building blocks available we speculated that a single rhodium-catalyst could mediate an initial alkene or alkyne hydroacylation reaction,5 and then a Suzuki-type cross-coupling, to convert enals 1 into difunctionalised products 2 in a single step, joining together three separate components. A variety of methods could then be used to convert enones 2 into the fully saturated heterocycles. The design of the β-S-enals allows the S-atom to function as the directing atom for the initial chelation-controlled hydroacylation reaction, and then for the O-atom of the resultant enone to direct the Suzuki-type coupling. The use of aldehydes with β-S-directing groups in hydroacylation reactions is well established.6–9 In addition, our laboratory,10 and others,11 has recently reported on the required aryl methyl sulfide Suzuki chemistry, including a cascade reaction on a benzene-derived substrate.


image file: c6qo00057f-s2.tif
Scheme 2 Heterocycle-derived β-S-enals as building blocks towards saturated heterocycles.

We began by evaluating the basic reaction sequence using pyran-derived enal 1a, tert-butyl acetylene and p-tolyl boronic acid as the reaction partners (Scheme 3). Earlier precedent,10,12 and initial investigations,13 suggested that a Rh(I) catalyst incorporating the small-bite-angle bis-phosphine ligand dcpm should be able to mediate both of the key C–C bond forming reactions. When a catalyst of this type was generated in situ and applied to the targeted transformation, good yields of enone 2a were obtained. Achieving a short reaction time for the initial hydroacylation reaction was key to obtaining a high yield for the final product. Accordingly, warming to 55 °C resulted in the hydroacylation reaction being complete in only 5 minutes, with the following Suzuki-type coupling then requiring 5 hours. It was pleasing to note that the β-S-enal substrate appeared to allow significantly faster reactions than the previously explored fully aromatic system.


image file: c6qo00057f-s3.tif
Scheme 3 Establishing reaction conditions for the hydroacylation-Suzuki cascade sequence to prepare dihydropyran 2a.

With a catalyst and appropriate reaction conditions for the cascade process in hand, we next explored the scope of the alkynes and alkenes that could be employed in the hydroacylation step. Given the importance of N-heterocycles in medicinal chemistry, we chose the tetrahydropyridine substrate, 1b, in combination with tolyl boronic acid, as a suitable platform to evaluate the chemistry (Scheme 4). As can be seen the use of tert-butyl acetylene was successful, delivering the three-component product, enone 2b, in high yield. A terminal alkyne substituted with a benzyl ether (2c), and an internal alkyne (2d) were both successful substrates. Less sterically demanding alkyne substrates resulted in mixtures of linear and branched regioisomers in the hydroacylation step, resulting in lower overall yields. For example, phenyl acetylene (2e) and hex-5-ynenitrile (2f) delivered 4[thin space (1/6-em)]:[thin space (1/6-em)]1 and 5[thin space (1/6-em)]:[thin space (1/6-em)]1 mixtures of linear[thin space (1/6-em)]:[thin space (1/6-em)]branched isomers, respectively. Terminal alkenes could be employed in the desired cascade process, however, their lower reactivity in the hydroacylation step, relative to alkynes, necessitated the use of five equivalents to achieve suitably fast reactions. Using these conditions with octene delivered the desired three-component coupled product (2g) in 84% yield. Terminal alkenes substituted with bromo (2h), phenyl (2i) and free hydroxyl groups (2j) were also successfully employed. Disubstituted alkenes were unreactive in the described system.14


image file: c6qo00057f-s4.tif
Scheme 4 Substrate scope of the alkyne and alkene component in the cascade synthesis of tetrahydropyridines 2. Reaction conditions: 1b (1.0 equiv.), alkyne (1.5 equiv.) or alkene (5.0 equiv.), [Rh(nbd)2]BF4 (5 mol%), dcpm (5 mol%), acetone, 55 °C, 5–10 min; then p-tolyl boronic acid (1.5 equiv.), Ag2CO3 (1.0 equiv.), 55 °C, 5 h. Isolated yields of the major isomer. aMeasured by 1H NMR spectrometry on the crude reaction mixture.

Tetrahydropyridine enal 1b was then used to evaluate the scope of the boronic acid coupling partner (Scheme 5). Initially employing tert-butyl acetylene as the hydroacylation coupling partner, a range of electronically varied aryl boronic acids could be readily employed (2k–2p), including halogen substituents. Although substitution at the meta-position was possible (2n), attempts to employ ortho-substituted boronic acids were unsuccessful. A heterocyclic boronic acid, in the form of 3-thienyl, and also an alkenyl boronic acid performed well (2q and 2r). Using octene as the hydroacylation coupling partner allowed a similar range of boronic acids to be successfully incorporated into the cascade process (2s–2x).


image file: c6qo00057f-s5.tif
Scheme 5 Substrate scope of the boronic acid component in the cascade synthesis of tetrahydropyridines 2. Reaction conditions: 1b (1.0 equiv.), alkyne (1.5 equiv.) or alkene (5.0 equiv.), [Rh(nbd)2]BF4 (5 mol%), dcpm (5 mol%), acetone, 55 °C, 5–10 min; then boronic acid (1.5 equiv.), Ag2CO3 (1.0 equiv.), 55 °C, 5 h. Isolated yields.

One of the goals of the present chemistry was to show that a variety of different heterocycles could be accessed using a single strategy. Accordingly, in Scheme 6 we demonstrate the successful use of N-, O-, and S-based heterocyclic building blocks. For O-based heterocycles, a dihydropyran and a 2H-chromene-based substrate were both combined successfully with alkene and alkyne coupling partners and aryl boronic acids (2a, 3a–3d). S-heteocycles were represented by a 2H-thiochromene-based substrate, which was employed without incident (3e, 3f). Unfortunately, it was not possible to prepare the dihydrothiopyran substrate due to stability issues. Finally, in addition to tetrahydropyridine substrate 1b already described, we were able to prepare and exploit a tropane-based substrate (1e), allowing access to alkyne and alkene coupled products in good yields (3g and 3h).


image file: c6qo00057f-s6.tif
Scheme 6 Variation of the heterocyclic enal component in the preparation of di-coupled products 3. Reaction conditions: 1 (1.0 equiv.), alkyne (1.5 equiv.) or alkene (5.0 equiv.), [Rh(nbd)2]BF4 (5 mol%), dcpm (5 mol%), acetone, 55 °C, 5–10 min; then boronic acid (1.5 equiv.), Ag2CO3 (1.0 equiv.), 55 °C, 5 h. Isolated yields.

All of the scoping experiments described in Schemes 4–6, were performed on a relatively small scale (0.2 mmol of enal), and as such 5 mol% of catalyst was employed due to ease of use. However, for larger preparative scale reactions, it was possible to lower the catalyst loading. Scheme 7 shows the use of tetrahydropyridine substrate 1b, and tropane-derived substrate 1e, used in alkene hydroacylation initiated cascades, employing just 3 mol% of catalyst, to deliver gram scale quantities of coupled products (2g and 3i) in excellent yields.


image file: c6qo00057f-s7.tif
Scheme 7 Preparative scale synthesis of products 2g and 3i.

Finally, as an illustration of synthetic potential of the enone products obtained from the developed cascade processes, we have shown that tetrahydropyridine-derived product 2g undergoes high-yielding detosylation and alkene reduction in a single-step, providing piperidine 4 (Scheme 8). This one-step transformation was achieved using magnesium metal in methanol under sonication conditons.15


image file: c6qo00057f-s8.tif
Scheme 8 One-step deprotection and reduction of enone 2g.

In conclusion, we have shown that heterocycle-derived β-S-enals are efficient substrates for rhodium-catalysed hydroacylation-Suzuki type coupling cascade processes. Both alkyne and alkene hydroacylation reactions can be used as the initial C–C bond-forming event, and a variety of boronic acids can be employed as substrates in the Suzuki-type coupling. The products are obtained in good to excellent yields, and show potential as precursors to access biologically relevant compounds.

Acknowledgements

We thank the EPSRC for the award of an Established Career Fellowship (MCW).

Notes and references

  1. (a) T. J. Ritchie, S. J. F. Macdonald, R. J. Young and S. D. Pickett, Drug Discovery Today, 2011, 16, 164 CrossRef CAS PubMed; (b) F. Lovering, J. Bikker and C. Humblet, J. Med. Chem., 2009, 52, 6752 CrossRef CAS PubMed.
  2. (a) Y. Yuan, C. K. Arnatt, N. El-Hage, S. M. Dever, J. C. Jacob, D. E. Selley, K. F. Hauser and Y. Zhang, Med. Chem. Commun., 2013, 4, 847 RSC; (b) D. Šakić, F. Achrainer, V. Vrček and H. Zipse, Org. Biomol. Chem., 2013, 11, 4232 RSC; (c) Y. Yuan, C. K. Arnatt, G. Li, K. M. Haney, D. Ding, J. C. Jacob, D. E. Selley and Y. Zhang, Org. Biomol. Chem., 2012, 10, 2633 RSC; (d) P. C. Meltzer, P. Blundell, T. Zona, L. Yang, H. Huang, A. A. Bonab, E. Livni, A. Fischman and B. K. Madras, J. Med. Chem., 2003, 46, 3483 CrossRef CAS PubMed; (e) S. D. Banister, I. A. Moussa, C. Beinat, A. J. Reynolds, P. Schiavini, W. T. Jorgensen and M. Kassiou, Bioorg. Med. Chem. Lett., 2011, 21, 38 CrossRef CAS PubMed; (f) R. K. Razdan, Pharmacol. Rev., 1986, 38, 75 CAS.
  3. (a) E. Vitaku, D. T. Smith and J. T. Njardarson, J. Med. Chem., 2014, 57, 10257 CrossRef CAS PubMed; (b) C.-V. T. Vo and J. W. Bode, J. Org. Chem., 2014, 79, 2809 CrossRef CAS PubMed.
  4. A two-step process is employed, involving initial conversion of the parent ketone into the corresponding β-halo-enal, followed by substitution of the halogen substituent with a methyl sulfide: D. R. Williams, L. A. Robinson, C. R. Nevill and J. P. Reddy, Angew. Chem., Int. Ed., 2007, 46, 915 CrossRef CAS PubMed.
  5. (a) M. C. Willis, Chem. Rev., 2010, 110, 725 CrossRef CAS PubMed; (b) C.-H. Jun, E.-A. Jo and J.-W. Park, Eur. J. Org. Chem., 2007, 1869 CrossRef CAS.
  6. Selected examples: (a) M. C. Willis, S. J. McNally and P. J. Beswick, Angew. Chem., Int. Ed., 2004, 42, 340 CrossRef PubMed; (b) M. C. Willis and R. L. Woodward, J. Am. Chem. Soc., 2005, 127, 18012 CrossRef CAS PubMed; (c) G. L. Moxham, H. E. Randell-Sly, S. K. Brayshaw, R. L. Woodward, A. S. Weller and M. C. Willis, Angew. Chem., Int. Ed., 2006, 45, 7618 CrossRef CAS PubMed; (d) J. D. Osborne and M. C. Willis, Chem. Commun., 2008, 5025 RSC; (e) G. L. Moxham, H. Randell-Sly, S. K. Brayshaw, A. S. Weller and M. C. Willis, Chem. – Eur. J., 2008, 14, 8383 CrossRef CAS PubMed; (f) S. R. Parsons, J. F. Hooper and M. C. Willis, Org. Lett., 2011, 13, 998 CrossRef CAS PubMed; (g) R. Pawley, M. Huertos, G. Lloyd-Jones, A. S. Weller and M. C. Willis, Organometallics, 2012, 31, 5650 CrossRef CAS; (h) S.-J. Poingdestre, J. D. Goodacre, A. S. Weller and M. C. Willis, Chem. Commun., 2012, 48, 6354 RSC.
  7. Examples of alternative chelating groups in intermolecular hydroacylation reactions: O-chelation; (a) K. Kokubo, K. Matsumasa, M. Miura and M. Nomura, J. Org. Chem., 1997, 62, 4564 CrossRef CAS; (b) M. Imai, M. Tanaka, K. Tanaka, Y. Yamamoto, N. Imai-Ogata, M. Shimowatari, S. Nagumo, N. Kawahara and H. Suemune, J. Org. Chem., 2004, 69, 1144 CrossRef CAS PubMed; (c) J.-H. Zhang and C. Bolm, Org. Lett., 2011, 13, 3900 CrossRef PubMed; (d) M. von Delius, C. M. Le and V. M. Dong, J. Am. Chem. Soc., 2012, 134, 15022 CrossRef CAS PubMed; (e) X.-W. Du and L. M. Stanley, Org. Lett., 2015, 17, 3276 CrossRef CAS PubMed, N-Chelation; (f) J. W. Suggs, J. Am. Chem. Soc., 1979, 101, 489 CrossRef CAS; (g) C.-H. Jun, H. Lee and J.-B. Hong, J. Org. Chem., 1997, 62, 1200 CrossRef CAS; (h) N. R. Vautravers, D. D. Regent and B. Breit, Chem. Commun., 2011, 47, 6635 RSC; (i) T. Zhang, Z. Qi, X. Zhang, L. Wu and X. Li, Chem. – Eur. J., 2014, 20, 3283 CrossRef CAS PubMed; (j) M. Castaing, S. L. Wason, B. Estepa, J. F. Hooper and M. C. Willis, Angew. Chem., Int. Ed., 2013, 52, 13280 CrossRef CAS PubMed.
  8. For a review of non-chelation-controlled hydroacylation reactions: J. C. Leung and M. J. Krische, Chem. Sci., 2012, 3, 2202 RSC.
  9. Examples of non-chelation-controlled hydroacylation reactions: (a) T. B. Marder, D. C. Roe and D. Milstein, Organometallics, 1988, 7, 1451 CrossRef CAS; (b) T. Kondo, M. Akazome, Y. Tsuji and Y. Watanabe, J. Org. Chem., 1990, 55, 1286 CrossRef CAS; (c) T. Tsuda, T. Kiyoi and T. Saegusa, J. Org. Chem., 1990, 55, 2554 CrossRef CAS; (d) C. P. Lenges, P. S. White and M. Brookhart, J. Am. Chem. Soc., 1998, 120, 6965 CrossRef CAS; (e) A. H. Roy, C. P. Lenges and M. Brookhart, J. Am. Chem. Soc., 2007, 129, 2082 CrossRef CAS PubMed; (f) S. Omura, T. Fukuyama, J. Horiguchi, Y. Murakami and I. Ryu, J. Am. Chem. Soc., 2008, 130, 14094 CrossRef CAS PubMed; (g) F. Shibahara, J. F. Bower and M. J. Krische, J. Am. Chem. Soc., 2008, 130, 14120 CrossRef CAS PubMed; (h) V. M. Williams, J. C. Leung, R. L. Patman and M. J. Krische, Tetrahedron, 2009, 65, 5024 CrossRef CAS PubMed; (i) Q.-A. Chen, D. K. Kim and V. M. Dong, J. Am. Chem. Soc., 2014, 136, 3772 CrossRef CAS PubMed.
  10. J. F. Hooper, R. D. Young, I. Pernik, A. S. Weller and M. C. Willis, Chem. Sci., 2013, 4, 1568 RSC.
  11. F. Pan, H. Wang, P.-X. Shen, J. Zhao and Z.-J. Shi, Chem. Sci., 2013, 4, 1573 RSC.
  12. (a) A. B. Chaplin, J. F. Hooper, A. S. Weller and M. C. Willis, J. Am. Chem. Soc., 2012, 134, 4885 CrossRef CAS PubMed; (b) I. Pernik, J. F. Hooper, A. B. Chaplin, A. S. Weller and M. C. Willis, ACS Catal., 2012, 2, 2779 CrossRef CAS.
  13. See ESI for details.
  14. A. Prades, M. Fernández, S. D. Pike, M. C. Willis and A. S. Weller, Angew. Chem., Int. Ed., 2015, 54, 8520 CrossRef CAS PubMed.
  15. B. Nyasse, L. Grehn and U. Ragnarsson, Chem. Commun., 1997, 1017 RSC.

Footnote

Electronic supplementary information (ESI) available: Experimental details and supporting characterisation data. See DOI: 10.1039/c6qo00057f

This journal is © the Partner Organisations 2016